Abstract
BRCA1/2 mutation carriers diagnosed with breast cancer have a strongly elevated life-time risk of developing a contralateral tumour. We studied the contralateral breast cancer risk in 164 patients from 83 families with a proven BRCA1 mutation in relation to the age at diagnosis of the first primary breast cancer. In the actuarial outcomes after 10 years' follow-up, 40% of the 124 BRCA1-patients diagnosed with breast cancer < 50 years had developed contralateral breast cancer, vs 12% of the 40 patients > 50 years at first diagnosis (Plogrank= 0.02). These data suggest that age at diagnosis of the first tumour should be taken into account when prophylactic mastectomy in BRCA1-patients is considered. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adami HO, Bergstrom R and Hansen J (1985) Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer 55: 643–647
Anderson DE (1971) Some characteristics of familial breast cancer. Cancer 28: 1500–1505
Broët P, de la Rochefordière, Scholl SM, Fourquet A, Mosseri V, Durand J-C, Pouillart P and Asselain B (1995) Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 13: 1578–1583
Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467
Easton DF, Ford D and Bishop DT, and the Breast Cancer Linkage Consortium (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56: 265–271
Ford D, Easton DF, Bishop DT, Narod SA and Goldgar DE and the Breast Cancer Linkage Consortium (1994) Risk of cancer in BRCA1 mutation carriers. Lancet 343: 692–695
Ford D, Easton DF and Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57: 1457–1462
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop T, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A and Zelada-Hedman M and the Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62: 676–689
Hislop TG, Elwood JM, Coldmann AJ, Spinelli JJ, Worth JJ and Ellison LG (1984) Second primary cancer of the breast: incidence and risk factors. Br J Cancer 49: 70–85
Hogervorst FBL, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JGM, Vasen HFA, Meijers-Heijboer H, Menko FH, Cornelisse CJ, den Dunnen JT, Devilee P and van Ommen GJB (1995) Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10: 208–212
Newman B, Mu H, Butler LM, Millikan RC, Moorman PG and King MC (1998) Frequency of breast cancer attributable to BRCA in a population-based series of American women. JAMA 279: 915–921
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J and Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91: 943–949
Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drüsedau M, Hogervorst FLB, Hageman S, Arts PJW, Ligtenberg MJL, Meijers-Heijboer H, Klijn JGM, Vasen HFA, Cornelisse CJ, van't Veer LJ, Bakker E, van Ommen GJB and Devilee P (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17: 341–345
Prior P and Waterhouse JA (1978) Incidence of bilateral tumours in a population-based series of breast-cancer patients. I. Two approaches to an epidemiological analysis. Br J Cancer 37: 620–634
Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L and Offit K (1998) BRCA-associated breast cancer in young women. J Clin Oncol 16: 1642–1649
Verhoog LC, Brekelmans CTM, Seynaeve C, van den Bosch LMC, Dahmen G, van Geel AN, Tilanus-Linthorst MMA, Bartels CCM, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ and Klijn JGM (1998) Survival and tumour characteristics of breast-cancer patients with germline mutations in BRCA1. Lancet 351: 316–321
Verhoog LC, Brekelmans CTM, Seynaeve C, Dahmen G, van Geel AN, Bartels CCM, Tilanus-Linthorst MMA, Wagner A, Devilee P, Halley DJJ, van den Ouweland AMW, Meijers-Heijboer EJ and Klijn JGM (1999) Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17: 3396–3402
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Verhoog, L., Brekelmans, C., Seynaeve, C. et al. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 83, 384–386 (2000). https://doi.org/10.1054/bjoc.2000.1239
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1239
Keywords
This article is cited by
-
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers
Breast Cancer Research and Treatment (2022)
-
Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis
Cancer Cell International (2021)
-
Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women
Breast Cancer Research and Treatment (2019)
-
Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis
Familial Cancer (2015)
-
Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis
Breast Cancer (2015)
